Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Novolog
|
| gptkbp:activities |
mimics natural insulin
|
| gptkbp:approves |
gptkb:2017
|
| gptkbp:brand |
gptkb:Fiasp
|
| gptkbp:clinical_trial |
type 2 diabetes
type 1 diabetes conducted for safety conducted for efficacy |
| gptkbp:contraindication |
severe hypoglycemia
diabetic ketoacidosis hypersensitivity to insulin aspart |
| gptkbp:developed_by |
gptkb:Novo_Nordisk
|
| gptkbp:dosage_form |
subcutaneous injection
|
| gptkbp:duration |
up to 5 hours
|
| gptkbp:education |
proper injection technique
recognize hypoglycemia symptoms monitor blood glucose dietary considerations exercise impact on insulin |
| gptkbp:form |
gptkb:tablet
vial |
| gptkbp:formulation |
gptkb:insulin_aspart
|
| gptkbp:healthcare |
gptkb:software_framework
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fiasp
|
| gptkbp:indication |
mealtime insulin
|
| gptkbp:ingredients |
gptkb:insulin_aspart
|
| gptkbp:interacts_with |
gptkb:beer
beta-blockers other antidiabetic medications |
| gptkbp:is_used_for |
diabetes management
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:marketed_as |
multiple countries
Novo Nordisk brand |
| gptkbp:packaging |
vials
pre-filled pens |
| gptkbp:pharmacokinetics |
lowers blood glucose levels
rapid absorption peak effect at 1-3 hours |
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:premiered_on |
within 20 minutes
|
| gptkbp:provides_information_on |
recommended for mealtime use
used in insulin pumps |
| gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:EMA |
| gptkbp:research |
long-term safety studies
ongoing efficacy studies comparative studies with other insulins |
| gptkbp:scholarships |
available for users
|
| gptkbp:shelf_life |
28 days after opening
up to 36 months unopened |
| gptkbp:side_effect |
nausea
allergic reactions weight gain injection site reactions hypoglycemia reported in clinical trials |
| gptkbp:storage |
refrigerated
|